Takeda Partners With Universities on Research Into GI and Liver Disorders

Takeda Partners With Universities on Research Into GI and Liver Disorders
Takeda Pharmaceuticals has entered a five-year research collaboration with New York University and Columbia University to discover and develop new therapies for people with gastrointestinal and liver disorders. Gut inflammation, which underlies several medical conditions, such as inflammatory bowel disease (IBD) and celiac disease, is among the target areas of interest. The collaborative research alliance will take advantage of Takeda’s research, development, and funding capabilities to boost existing gastroenterology research and early-stage technologies at NYU and Columbia. The pharmaceutical company will fund the most promising and innovative projects, which, if successful, may be eligible for additional funding for larger studies. “Takeda looks forward to working together with the universities to successfully bring forth the most innovative, differentiated ideas to design and translate early research into therapeutics for patients with significant unmet liver and gastrointestinal disorders,” Gareth Hicks, PhD, head of Takeda’s gastrointestinal drug discovery unit, said in an NYU press release. “Through this unique partnership between academia and industry, our goal is to develop better [therapies] for common yet debilitating diseases of the liver and gastrointestinal system that are not well managed by existing therapies,” said Nigel Bunnett, PhD, professor and chair of the department of molecular pathobiology at NYU College of Dentistry, who will lead the collaboration at the university. Notably, Bunnett and other NYU and Columbia researchers were recently part of an international team that identified a promising target for chronic pain relief in IBD. Published earlier this year in the journal Proceedings of the National Academy of Sc
Subscribe or to access all post and page content.